| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2137059 | Leukemia Research | 2013 | 8 Pages |
Abstract
CCND1, FGFR3 and c-MAF mRNA expression of tumor samples from 123 multiple myeloma patients were analyzed by global RQ/RT-PCR. CCND1, FGFR3 and c-MAF were positive in 44 (36%), 28 (23%) and 16 (13%) of patients, respectively. In 7 patients, both FGFR3 and c-MAF were positive. The expression of c-MAF was independent unfavorable prognostic factors for overall survival (OS). Autologous stem cell transplantation improved progression-free survival of CCND1-positive patients. Bortezomib, thalidomide or lenalidomide extended OS of FGFR3 and/or c-MAF-positive patients. Thus, CCND1, FGFR3 and c-MAF mRNA expression can predict survival and is useful for planning stratified treatment strategies for myeloma patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Atsushi Inagaki, Emi Tajima, Miyuki Uranishi, Haruhito Totani, Yu Asao, Hiroka Ogura, Ayako Masaki, Tatsuya Yoshida, Fumiko Mori, Asahi Ito, Hiroki Yano, Masaki Ri, Satoshi Kayukawa, Takae Kataoka, Shigeru Kusumoto, Takashi Ishida, Yoshihito Hayami,